Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting

“ASH provides an outstanding forum to highlight our advancing pre-clinical IND-candidate programs,” said Edward Lanphier, Sangamo’s president and CEO. “In particular, and for the first time, we will provide details of our ZFP Therapeutic approach to the treatment of sickle cell disease and b-thalassemia. Additionally, we will update on progress in our In Vivo Protein Replacement Platform (IVPRP), specifically our programs in hemophilia A and B. The ASH meeting also provides an excellent opportunity to highlight the breadth and depth of our ZFP Therapeutic platform. Data will also be presented from our activities in hematopoietic stem-cell manufacturing and applications in transplantation, as well as in zinc finger nuclease (ZFN) modified T-cells for oncology applications.”

The following are specific details regarding Sangamo’s presentations at the conference:

Oral Presentations:
Monday, December 9
Using Forced Chromatin Looping to Overcome Developmental Silencing Embryonic and Fetal beta-Type Globin Genes in Adult Erythroid Cells (Abstract #433) 2:45 PM-4:15 PM
Session: 112. Thalassemia and Globin Gene Regulation: Targeted Engineering of Globin Gene Expression, 343-345 (Ernest N. Morial Convention Center)

Targeted Gene Modification in Hematopoietic Stem Cells: A Potential Treatment for Thalassemia and Sickle Cell Anemia (Abstract#434) 2:45 PM-4:15 PM
Session: 112. Thalassemia and Globin Gene Regulation: Targeted Engineering of Globin Gene Expression, 343-345 (Ernest N. Morial Convention Center)

ZFN Mediated Targeting of Albumin “Safe Harbor” Results in Therapeutic Levels of Human Factor VIII in a Mouse Model of Hemophilia A (Abstract#720) 4:30 PM-6:00 PM
Session: 801. Gene Therapy and Transfer: Advances of gene therapy for inherited diseases, Riverside Rooms – R04-R05 (Ernest N. Morial Convention Center)

Poster Presentations:
Saturday, December 7
ZFN-Driven Gene Editing Prevents HLA-A Expression on Hematopoietic Stem Cells —Improving the Chance of Finding an HLA-Matched Donor (Abstract# 1655) 5:30 PM-7:30 PM
Session: 801. Gene Therapy and Transfer: Poster I, Hall E (Ernest N. Morial Convention Center)

Sunday, December 8
Zinc Finger Nucleases Targeting the beta-Globin Locus Drive Efficient Correction of the Sickle Mutation in CD34+ Cells (Abstract#2904) 6:30 PM-8:30 PM
Session: 801. Gene Therapy and Transfer: Poster II, Hall E (Ernest N. Morial Convention Center)

TCR Gene Editing Achieved in a Single Round of T-Cell Activation is Sufficient to Redirect T-Cell Specificity and Prevent GvHD (Abstract#2898) 6:30 PM-8:30 PM
Session: 801. Gene Therapy and Transfer: Poster II, Hall E (Ernest N. Morial Convention Center)

Monday, December 9
Autologous Hematopoietic Stem/Progenitor Cell (HSPC) Therapy for Monogenic Blood Disorders: Scalable, cGMP-Compliant Process for Generating Highly Efficient Genome Edited HSPC (Abstract# 4213) 6:00 PM-8:00 PM
Session: 801. Gene Therapy and Transfer: Poster III, Hall E (Ernest N. Morial Convention Center)

All abstracts for the meeting are available online at 2013 ASH Meeting Abstracts.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer’s disease. Sangamo’s other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington’s disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciencesand Sigma-Aldrich Corporation. For more information about Sangamo, visit the company’s website at www.sangamo.com

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references relating to research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo’s ZFP technology platform, the potential of Sangamo’s ZFP technology to treat hemophilia, hemoglobinopathies, and  other inherited genetic diseases as well as applications in stem cell transplantation and oncology. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of ZFNs and ZFP TFs, technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo’s public filings with the Securities and Exchange Commission, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.